Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nippon Shinyaku Licenses Leukemia Drug Marketing Rights In Korea To Korean Company

This article was originally published in PharmAsia News

Executive Summary

Nippon Shinyaku signed a license agreement Dec. 4 with Korean drug seller BL&H and provided the company exclusive marketing rights to acute promyelocytic leukemia drug Trisenox (arsenic trioxide) in South Korea. Nippon Shinyaku obtained the manufacturing and marketing rights in Japan and Korea from U.S. drug maker Cephalon in 2002, and started manufacturing and marketing it in Japan in 2004, but the company has not marketed the drug in South Korea. Payment details were not disclosed. BL&H plans to market the drug in spring 2010. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts